| Objective: This paper investigated the influence of the efficacy and the survival time of ERCC1, BRCA1 and GSTP1 genes on non-small cell lung cancer(NSCLC) patients with platinum-based chemotherapy, and further analyzed the relationship between expression of three genes and NSCLC general clinical data, exploring individualized and targeted selection of platinum-based chemotherapy for NSCLC.Methods: We reviewed 54 patients who were histologically and radiologically diagnosed with advanced cancer during January 2013 and November 2014 in our hospital and initially treated with platinum-based chemotherapy, and used genetic testing method(ERCC1, BRCA1 and GSTP1 genetic expression) to analyze chemotherapy efficacy.Results:(1) In this study, the total effective rate of 54 cases of NSCLC patients was 51.9%. It was 26.32% in ERCC1 positive expression group, 65.71% in negative group, p = 0.006%; 18.51% in BRCA1 positive expression group, 33.33% in negative expression group, p = 0.014%; 9.20 % in GSTP1 expression wild group, 42.59% in mutant group, p = 0.267%.(2) ERCC1 survival time of negative group(26.9 months) was longer than positive group(17.6 months), which was statistically significant(P = 0.000); BRCC1 survival time of negative group(28.4 months) was longer than positive group(20.6 months), which was statistically significant(P = 0.000); Comparing GSTP1 survival time of mutant group withthat of wild group had no significant difference(P = 0.081).(3) Though multivariate analysis we got that PS score, ERCCA1 expression and BRCA1 expression were independent factors affecting survival.Conclusions:(1) ERCC1, BRCA1 and GSTP1 genes are sensitive genes of chemotherapy of platinum-based chemotherapy;(2) For NSCLC patients with cisplatin chemotherapy, the expression of ERCC1 and BRCA1 may be the important predictors, which provide help for individual treatment.(3) GSTP1 is significantly valuable for the judgment of cisplatin treatment of NSCLC, but it still needs more clinical research evidence. |
PDF Full Text Request